Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bayer Ag ADR (OP:BAYRY)

15.66 -0.01 (-0.06%)
Delayed Quote Updated: 3:59 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 545,421
Open 15.63
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 15.67
Today's Range 15.60 - 15.71
52wk Range 7.650 - 15.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...
From Bayer
Via Business Wire
News headline image
Bayer and America’s Grow-a-Row Continue Partnership to Fight Food Insecurity
From Bayer
Via Business Wire

Performance

52-Week Range 2.0% below 52-week high
15.66
7.6552W Low 15.9852W High
1 Week 2.0% below 1-week high
15.541W Low 15.981W High

Bayer Ag ADR (BAYRY) traded between $7.65 and $15.98 over the past 52 weeks and last traded at $15.66, 2.0% below its 52-week high. Over the past week it ranged between $15.54 and $15.98.

Past 12 Months
-1.6%
+26.1%
+13.2%
+42.1%
+41.2%
+91.2%
1W -$0.25
1M +$3.24
3M +$1.82
6M +$4.64
YTD +$4.57
1Y +$7.47

BAYRY was +91.2% over the past year, +42.1% over six months, +41.2% year to date, -1.6% in the last week.

12 Months vs Market
BAYRY
+91.2%
DIA
+10.9%
SPY
+12.3%
QQQ
+11.7%
IWM
+16.9%

Over the past 12 months BAYRY returned +91.2% versus DIA (Dow) +10.9%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +11.7% and IWM (Russell 2000) +16.9%.

Volume & Liquidity 0.88× 3-mo avg
Today 545,421 3-mo avg 618.0K
1W
1.4M
1M
881.3K
3M
618.0K
6M
914.2K
YTD
1.1M
1Y
1.0M

BAYRY most recently traded 545,421 shares against a 3-month average daily volume of 618.0K.

More News

Read More
News headline image
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions
From Bayer
Via Business Wire
News headline image
Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting
From Bayer
Via Business Wire
News headline image
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
From Bayer
Via Business Wire
News headline image
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
From Bayer
Via Business Wire
News headline image
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
From Bayer
Via Business Wire
News headline image
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
From Bayer
Via Business Wire
News headline image
Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
From Bayer
Via Business Wire
News headline image
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
From Bayer
Via Business Wire
News headline image
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
From Bayer
Via Business Wire
News headline image
Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
From Bayer
Via Business Wire
News headline image
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
From Bayer
Via Business Wire
News headline image
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
From Bayer
Via Business Wire
News headline image
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
From Bayer
Via Business Wire
News headline image
One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
From Bayer
Via Business Wire
News headline image
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
From Bayer
Via Business Wire
News headline image
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
From Bayer
Via Business Wire
News headline image
Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
From Bayer
Via Business Wire
News headline image
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
From Bayer
Via Business Wire
News headline image
Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
From Bayer
Via Business Wire

Frequently Asked Questions

Is Bayer Ag ADR publicly traded?
Yes, Bayer Ag ADR is publicly traded.
What exchange does Bayer Ag ADR trade on?
Bayer Ag ADR trades on the OTC Traded
What is the ticker symbol for Bayer Ag ADR?
The ticker symbol for Bayer Ag ADR is BAYRY on the OTC Traded
What is the current price of Bayer Ag ADR?
The current price of Bayer Ag ADR is 15.66
When was Bayer Ag ADR last traded?
The last trade of Bayer Ag ADR was at 11/13/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.